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TGF-b1 Slows the Growth of Pathogenic
Myofibroblasts through a Mechanism Requiring the
Focal Adhesion Protein, Hic-5
Ganary Dabiri1, David A. Tumbarello2, Christopher E. Turner2 and Livingston Van De Water1
Pathogenic scarring is a devastating disorder that impairs normal tissue function after injury. Differentiated
myofibroblasts deposit and organize scars over a continuum, from normal to pathogenic, and yet the
mechanisms regulating their appearance and disappearance from tissues are enigmatic. We reported previously
that key functions of myofibroblasts derived from hypertrophic scars (HTSF) are constitutively activated by an
autocrine loop involving transforming growth factor-b1 (TGF-b1). We now report that this autocrine induction of
TGF-b1 results in a constitutively high level of Hic-5, which markedly reduces HTSF proliferation relative to
normal adult human dermal fibroblasts (NADF) without changing apoptosis. Cyclin D1 and A levels are
constitutively lower in HTSF compared to NADF, and the cyclin-dependent kinase inhibitor p21cip1 is
upregulated in HTSF and located in the nucleus. Inhibition of autocrine TGF-b1 production in HTSF reverses this
process, lowering Hic-5 and p21cip1 levels and increasing replication. Moreover, Hic-5 is partially localized in the
nucleus of HTSF, and knocking down Hic-5 with specific siRNAs in these cells results in decreased p21cip1 levels
and a concomitant increase in proliferation. Our findings show that autocrine production of TGF-b1 upregulates
the expression of Hic-5, which is essential for perpetuating the decreased proliferation seen in this pathogenic
myofibroblast.
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INTRODUCTION
Pathogenic fibrosis comprises a constellation of diseases in
which the excessive and chronic deposition of scar proteins
reduces organ function, impairs joint mobility, and compro-
mises psychological well-being. It is generally understood that
pathogenic fibrosis is initiated by the robust differentiation of
fibroblasts into myofibroblasts, and the over stimulation of these
cells during wound healing leads to excessive scar deposition
and contraction. It has been extensively shown that TGF-b1 is
central to these processes (Roberts et al., 2006). However, the
cellular mechanisms controlling fibroblast differentiation and
myofibroblast persistence are still largely unknown.
One type of fibrotic disorder, hypertrophic scars (HTS),
develops after deep dermal injury or full-thickness wounds
involving the deep dermis. HTS tend to be thick, erythema-
tous, raised, painful, pruritic, and remain within the boundary
of the original trauma site. Histological examination of HTS
shows distinct nodules that contain fine collagen fibers and
an excessive number of a-smooth muscle cell actin-positive
fibroblasts (Ehrlich et al., 1994). These characteristics are
perpetuated by the autocrine production and activation of
TGF-b1 (Scott et al., 2000; Tomasek et al., 2002). Because
large numbers of myofibroblasts persist in these nodules, it is
widely believed that these cells are hyperproliferating, hence,
its characterization in the literature as a fibroproliferative
disorder (Tredget et al., 1997). To date, however, there have
been no definitive studies examining the mechanisms linking
autocrine induction of TGF-b1 to cell-cycle regulation of
fibroblasts from hypertrophic scars (HTSFs) or other fibro-
genic myofibroblasts.
TGF-b1 is a potent cytokine that inhibits the growth of
several types of cells (Huang and Huang, 2005); however, it
has been shown to be both pro-proliferative and antiproli-
ferative for fibroblasts (Lal et al., 2003; Campaner et al.,
2006). TGF-b is a member of a large superfamily of
polypeptide growth factors that are synthesized in latent
form, stored in the extracellular matrix and activated when
the latency-associated protein dissociates from the latent
TGF-b complex. Active TGF-b signals through transmem-
brane receptor serine/threonine kinases that activate a family
of cytoplasmic proteins called Smads. In turn, Smads
translocate into the nucleus to regulate the expression of
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target genes (Feng and Derynck, 2005). In addition to Smad
proteins, G proteins and mitogen-activated protein kinases
are also involved in the downstream signaling of TGF-b
family members (Moustakas and Heldin, 2005). The growth
inhibitory pathway of TGF-b1 is mediated through Smad-
independent and Smad-dependent mechanisms, through
which the expression of the cell-cycle inhibitors, p21cip1,
p27kip1, and p15ink4b, is regulated (Hu et al., 1998).
Hic-5 is a TGF-b-inducible and H2O2-inducible focal
adhesion protein that shuttles to the nucleus where it may
serve as a transcription factor (Shibanuma et al., 1994). Hic-5
is also a focal adhesion Lin11, Isl-1, Mec-3(LIM)-containing
protein with homology to paxillin and can interact with focal
adhesion kinase and vinculin (Thomas et al., 1999). Hic-5
includes four LD domains in its N-terminal half and four LIM
domains in its C-terminal half with a nuclear export signal in
LD3 (Brown and Turner, 2004). Hic-5 accumulates in the
nucleus in response to oxidants, such as H2O2, and it can
shuttle between focal adhesions and the nucleus through an
oxidant-sensitive nuclear export signal (Shibanuma et al.,
2003). Hic-5 is probably retained in the nucleus through a
mechanism requiring all four LIM domains that serve as an
unconventional nuclear localization sequence (Shibanuma
et al., 2003). In the nucleus, Hic-5 participates in the
transcriptional control of genes including c-fos and p21
(Shibanuma et al., 2004). Hic-5 is also markedly upregulated
during the TGF-b-induced, epithelial–mesenchymal transition
(Tumbarello and Turner, 2007).
Myofibroblasts persist for long intervals within HTS
lesions, and we have undertaken a series of studies to
examine the mechanisms that perpetuate the pathogenic
myofibroblast phenotype. Earlier we had reported that HTSF
contain supermature focal adhesions and elaborate an
autocrine TGF-b1 loop producing 20-fold higher levels of
active TGF-b1 compared to normal adult human dermal
fibroblasts (NADF) (Dabiri et al., 2006). In the course of these
studies, we observed that HTSF grow more slowly in culture
than do NADF. We now show that autocrine induction of
TGF-b1 results in decreased HTSF growth in culture,
concomitant with high levels of Hic-5 and p21cip1 and low
levels of cyclin A. These effects occur in the absence of
increased apoptosis. Silencing of Hic-5 by specific short
interference RNAs (siRNAs) reverses the effect of TGF-b1
seen in HTSF by causing downregulation of p21cip1,
upregulation of cyclin A, and restoration of proliferation to
normal rates. Our data link the autocrine induction of TGF-b1
with low cell proliferation through the focal adhesion protein,
Hic-5. Our data provide insight into a mechanism controlling
HTS proliferation; and may serve as a model for other fibrotic
disorders.
RESULTS
Autocrine induction of TGF-b1 decreases the proliferation of
HTSF
Previously, we established that HTSF produce and activate
much higher levels of TGF-b1 than do NADF, and that this
autocrine TGF-b1 loop results in the stable generation of
‘‘supermature’’ focal adhesions (Dabiri et al., 2006). During
the course of these studies, we observed that HTSF grew
slowly in culture and sought to determine whether autocrine
TGF-b1 production regulated HTSF proliferation. To inhibit
the TGF-b1 signaling produced by the autocrine production
of TGF-b1, we utilized a neutralizing antibody against TGF-
b1 (anti-TGF-b). To ensure that our blocking conditions were
specific and saturating, we cultured the Mink lung epithelial
cells–plasminogen activator inhibitor-1 (MLEC–PAI-1) repor-
ter-expressing cells alone and tested the ability of anti-TGF-b
to block the response generated by recombinant, active TGF-
b1. The PAI-1 promoter is regulated by TGF-b1, and the
MLEC–PAI-1 luciferase system is commonly used to evaluate
TGF-b1-mediated transcriptional activity (Abe et al., 1994).
We found that 10 ng/ml of anti-TGF-b blocked the response
of 5 ng/ml of active TGF-b1 (Figure 1a). Next, we co-cultured
HTSF or NADF with MLEC expressing the PAI-1 luciferase
construct, with or without the addition of anti-TGF-b (anti-
body to block TGF-b1 function, 20 mg/ml). Using this assay,
we observed that HTSF produce and activate TGF-b to a
greater extent (as determined by the luciferase activity)
compared to NADF. The addition of anti-TGF-b to NADF
and HTSF reduced the TGF-b-dependent response of the
PAI-1 promoter in the MLEC (Figure 1b).
Since active TGF-b1 has been shown to have inhibitory
effects in fibroblast proliferation, we next determined
whether autocrine induction of TGF-b1 dampened HTSF
proliferation and/or entry into S-phase. Growth curves were
conducted by culturing equal cell numbers (see Materials and
Methods) of either HTSF or NADF, in the presence or absence
of active TGF-b1 (10 ng/ml) (Figure 1c). To test the
dependence of HTSF proliferation on the autocrine produc-
tion of TGF-b1, anti-TGF-b was added to some cultures. Cell
numbers were determined at 0, 3, 5, and 7 days after
culturing, and we found that HTSF proliferated slower
compared to NADF (expressed here as the increase in cell
number by day 3; cell number at day 3 minus the cell number
at day 0). Time points taken at days 5 and 7 yielded the same
relative increase between days 0 and 3 (data not shown).
Addition of 10 ng/ml of TGF-b1 to NADF resulted in a
statistically significant decrease in proliferation to levels close
to that of HTSF (Figure 1c). In cultures of HTSF, inhibition of
autocrine produced TGF-b with an antibody to active TGF-b
resulted in a statistically significant increase in the growth
potential of HTSF to levels observed with NADF in the
absence of TGF-b1 (Figure 1c). Anti-TGF-b did not appreci-
ably alter the growth of NADF, indicating that the prolifera-
tion of these cells is not regulated by the autocrine production
of TGF-b.
To test HTSF and NADF for altered entry into S-phase,
cells were serum-starved overnight. The next day cells were
pulsed with BrdU for 24 hours and cultured in serum-
containing medium, and the percentage of cells incorporating
this tracer into DNA was determined. NADF without the
addition of TGF-b1 (10 ng/ml) (Figure 1d, I) after 24 hours had
significantly more BrdU-positive nuclei compared to HTSF
(Figure 1d, IV). Addition of 10 ng/ml of TGF-b1 to cultures of
NADF (Figure 1d, II) resulted in a statistically significant
decrease in the percent positive nuclei to levels observed in
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HTSF (Figure 1d, IV). Inhibition of the autocrine induction of
TGF-b1 in HTSF with exogenous anti-TGF-b (Figure 1d, VI)
resulted in a significant increase in BrdU-positive nuclei.
These data suggest that the autocrine induction of TGF-b1
blocks entry into S-phase, thereby decreasing HTSF prolifera-
tion. To determine whether the observed TGF-b1 inhibition
of proliferation was due to increased apoptosis, cells were
TUNEL stained, with or without the addition of TGF-b1
(10 ng/ml) or anti-TGF-b (20 mg/ml). Anisomycin was used as
a positive control and DMSO as a vehicle, negative control.
We found that the addition of TGF-b or anti-TGF-b did not
increase the expression of TUNEL-positive cells (Figure S1),
indicating that TGF-b1 is not inducing apoptosis in these
cells.
TGF-b1 controls the expression of major cell-cycle regulatory
molecules
Because we observed slower HTSF proliferation and
decreased BrdU incorporation compared to NADF, we next
determined whether TGF-b1 altered the levels of G1 cell-
cycle proteins. Cell lysates were obtained from either NADF
or HTSF cultured in serum-containing media for 24 hours,
either with or without the addition of TGF-b1 (10 ng/ml) or
anti-TGF-b (20 mg/ml). The levels of cyclins A and D1 were
approximately three-fold higher in NADF compared to HTSF
(Figure 2a). The addition of TGF-b1 to NADF resulted in
decreased cyclin A and cyclin D1 levels, similar to those of
HTSF control. Inhibition of the autocrine loop of TGF-b1
(anti-TGF-b) resulted in approximately a five- and a four-fold
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Figure 1. Autocrine induction of TGF-b1 results in decreased proliferation in HTSF. (a) To test specificity and stoichiometry, MLEC expressing the PAI-1
luciferase construct were incubated with recombinant active TGF-b1 (5 ng/ml) and/or anti-TGF-b1 (10 ng/ml). (b) MLECs expressing the PAI-1 luciferase
construct were co-cultured with either NADF or HTSF in the presence or absence of anti-TGF-b1 (20 mg/ml) RLU (relative luminescence). (c) Cells were
cultured in serum-containing media with or without the addition of exogenous TGF-b1 (10 ng/ml) or anti-TGF-b (20 mg/ml) for 72 hours, and cell growth was
determined using CyQUANT assay (increase in cell number at day 3 is calculated as cell number at day 3cell number at day 0). (d) Cells were incubated
in serum-free media for 24 hours, then serum was added and cells were pulsed with BrdU and TGF-b1 (10 ng/ml) or anti-TGF-b (20mg/ml) for 24 hours.
Cells were stained with BrdU (green) and DNA (blue). Percent positive BrdU was calculated as a ratio (# blue–green colocalization)/total # blue)100.
*Pp0.005, n¼ 3. Bar¼120 mm.
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increase in cyclin A and cyclin D1 levels in HTSF,
respectively, compared to HTSF control.
Regulation of cell-cycle progression occurs, in part, through
a balance in the cyclins and their inhibitors (Ravitz and
Wenner, 1997). Therefore, we sought to examine the
endogenous levels of each of the proteins. Since it has been
previously shown that TGF-b1 regulates the expression of
several cyclin-dependent kinase inhibitor proteins in the cip/
kip and ink4 families (Ravitz and Wenner, 1997), we
determined the effect of TGF-b1 on these inhibitors in control
and pathogenic fibroblasts. We found that p21cip1 and p15ink4b
were expressed at significantly lower levels in NADF compared
to HTSF (two- and six-fold in protein expression, respectively,
or seven-fold p21cip1 in mRNA; Figure 5a). Addition of TGF-b1
to NADF resulted in a statistically significant increase in the
levels of p21cip1 and p15ink4b compared to NADF without
TGF-b1 (2.5- and 5.3-fold increase, respectively). Inhibition of
TGF-b1 with a specific antibody in HTSF resulted in a
statistically significant decrease in the expression of p21cip1
and p15ink4b compared to HTSF–TGF-b1 (2- and 14-fold,
respectively). These results indicated that TGF-b1 controls the
expression of cell-cycle proteins; cyclins D1, A, p21cip1, and
p15ink4b and together point to a critical role for autocrine
TGF-b1 in regulating cell growth in HTSF (Figure 2a).
The endogenous expression and TGF-b1 control over p27kip1
were also analyzed. We found, that p27kip1 is upregulated
in HTSF compared to NADF; however, its expression was
not controlled by TGF-b1 (data not shown).
We also determined the subcellular localization of
the cyclin kinase inhibitors p15ink4b and p21cip1, since the
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Figure 2. G1/S cell-cycle proteins are regulated by TGF-b1. Cells were incubated in serum-containing media for 24 hours with or without the addition of
either TGF-b1 (10 ng/ml) or anti-TGF-b (20 mg/ml). (a) Cells were then lysed and directly resolved by SDS-PAGE (10 or 15%) and analyzed by Western blot
analysis (b) cells were fractionated into nuclear and cytoplasmic (cytosolic) fractions then resolved by SDS-PAGE (15%) gels, transferred to nitrocellulose
membrane and analyzed for the designated protein by Western blotting. Blots included markers for cytosolic (RhoGDI) and nuclear (H2A) fraction and for
protein loading (Erk 1/2). *Pp0.005, n¼ 3.
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majority of cell-cycle control occurs in the nucleus (Figure
2b). On subcellular fraction, we found that p15ink4b is
predominantly localized in the cytosol of both NADF and
HTSF, but its expression is upregulated in HTSF compared to
NADF (2.5-fold). However, p21cip1 was predominately
localized in the nucleus in both HTSF and NADF, but at a
5-fold higher expression level in HTSF compared to NADF.
These results suggested that p21cip1 is the major cyclin kinase
inhibitor controlled by TGF-b1 resulting in the decreased
proliferation seen in HTSF. Consistent with the absence of an
appreciable TGF-b autocrine loop in NADF, we observed no
significant differences in either the growth rate (Figure 1c),
BrdU incorporation rate (Figure 1d), or levels of cell-cycle
proteins with the addition of an antagonist to active TGF-b
(Figure 2a). Conversely, since HTSF secrete and activate their
own TGF-b1, the addition of exogenous TGF-b1 did not
significantly alter the growth, BrdU incorporation, or cell-
cycle proteins compared to HTSF without exogenous TGF-
b1. Addition of anti-TGF-b to HTSF did reverse the slow rate
of proliferation (Figures 1 and 2).
Hic-5 expression is regulated by the autocrine induction of
TGF-b1 and controls key molecules necessary for cell-cycle
progression in HTSF
As shown above, HTSF elaborate an autocrine loop of TGF-
b1, which resulted in the upregulation of p21cip1 and a slower
cellular replication compared to NADF (Figures 1 and 2).
Since HTSF constitutively express larger focal adhesions
(Dabiri et al., 2006), and cell growth can be regulated at the
focal adhesions via integrin signaling, we considered the
possibility that the effects that we observed were due to
alterations in focal adhesion signaling. We observed no
change in the levels of phosphorylation of either focal
adhesion kinase or Erk in either NADF or HTSF (data not
shown). However, Hic-5, a TGF-b1-inducible focal adhesion
protein, has also been reported to translocate to the nucleus
and activate the p21 promoter (Shibanuma et al., 2004).
Therefore, to test this alternative—that Hic-5 could be
regulating growth of HTSF—we first analyzed the expression
of Hic-5 in NADF versus HTSF. NADFs and HTSFs were
cultured in serum-containing media for 24 hours with or
without the addition of either TGF-b1 (10 ng/ml) or anti-TGF-
b (20 mg/ml). The cells were then lysed and analyzed for the
expression of Hic-5 (Figure 3a). HTSF constitutively ex-
pressed Hic-5 at a 2.5-fold higher level compared to NADF in
the absence of exogenous TGF-b1 (Figure 3a). The addition of
TGF-b1 to NADF significantly increased the expression of
Hic-5 to levels similar to HTSF. Inhibition of TGF-b1 by anti-
TGF-b resulted in a statistically significant decrease in the
endogenous expression of Hic-5 in HTSF (2.5-fold). These
results showed that Hic-5 is regulated by TGF-b1 in NADF
and that the autocrine induction of TGF-b1 in HTSF resulted
in constitutively high levels of endogenous Hic-5.
Since nuclear Hic-5 can regulate p21cip1 transcriptionally
(Shibanuma et al., 2004) and cytosolic Hic-5 can localize to
the focal adhesions (Thomas et al., 1999), we next
determined the localization of Hic-5 in NADF and HTSF.
On subcellular fractionation of NADF and HTSF (Figure 3b),
we observed minimal levels of Hic-5 in the nucleus and
cytosol of NADF without the addition of TGF-b1 compared to
HTSF (Figure 3b). The addition of TGF-b1 significantly
increased the levels of Hic-5 in the nucleus as well as
cytosol in NADF. Conversely, inhibition of TGF-b with anti-
TGF-b (20 mg/ml) significantly decreased the expression of
Hic-5 in the nucleus and cytosol of HTSF (Figure 3b).
Since the levels of Hic-5 were upregulated and Hic-5 is
present in the nucleus of HTSF, we determined whether
inhibition of Hic-5 in HTSF controlled the expression of cell-
cycle proteins. Either Hic-5 or control siRNAs were trans-
fected into either HTSF or NADF for 5 days. After the fifth
day, cells were trypsinized and cultured in the presence or
absence of TGF-b1 (10 ng/ml); after 24 hours cells were lysed
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Figure 3. Hic-5 expression is regulated by TGF-b1 and localized to the nucleus in HTSF. Cells were incubated in serum-containing media for 24 hours
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and protein expression levels analyzed (Figure 4a). Initially, a
pool of four siRNA was used, the pool was deconvolved and
two specific siRNAs to Hic-5 were employed. We observed,
both with the pooled (data not shown) and the individual
siRNAs (duplex #2, data not shown), a greater than 90%
decrease in the expression of Hic-5 in both NADF and HTSF
under basal conditions (Figure 4a). Hic-5 knockdowns also
efficiently blocked TGF-b1-mediated increases in Hic-5
expression (Figure 4a). We next determined the effect of
Hic-5 knockdown on p21cip1 levels. siRNA to Hic-5 resulted
in a five-fold decrease in the expression of p21cip1 in HTSF,
and the addition of exogenous TGF-b1 did not significantly
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restore the expression of p21cip1 in both NADF and HTSF.
The addition of TGF-b1 increased the expression p15ink4b in
NADF by four-fold; however, this upregulation was un-
affected by knockdown of Hic-5 (Figure 4a). Inhibiting the
expression of Hic-5 in HTSF increased the expression of
cyclins A and D1. In the absence of Hic-5, the addition of
exogenous TGF-b1 did not decrease the expression of both
cyclins A and D1 in NADF (Figure 4a). These data show that
Hic-5 is a necessary intermediate in TGF-b-dependent growth
modulation of HTSF and NADF.
To establish the specificity of the Hic-5 siRNA knockdown
in HTSF (primary human cell lines), we performed experi-
ments to rescue the expression of Hic-5 using an adenoviral
green fluorescent protein (GFP) construct expressing mouse
cDNA Hic-5. The siRNAs employed in our studies were
directed to human Hic-5 and differed at one or more bases
from the transduced mouse Hic-5 cDNA. We observed by
fluorescence microscopy efficient transduction by the mouse
adenoviral construct (490%) of targeted human cells (data
not shown). Upon rescue of Hic-5 siRNA transfected cells
with the Hic-5 adenovirus in HTSF, p21cip1 levels were
restored and the expression of cyclins D1 and A were once
again decreased (Figure 4b). Adenoviral rescue of Hic-5
siRNA duplex #2 yielded the same results as duplex #1 (data
not shown). These data show that Hic-5 is strictly necessary
as a downstream signaling target of TGF-b1-mediated control
over proliferation in HTSF.
Hic-5 overexpression is sufficient to control molecules
necessary for cell-cycle progression in NADF
We found that addition of TGF-b1 to NADF was sufficient to
increase the expression of Hic-5 (Figure 3a) and decrease the
growth of NADF (Figure 1c and d). Therefore, we next
determined whether overexpressing Hic-5 in NADF was
sufficient to control cell-cycle proteins under conditions in
which adenovirus yielded greater than 90% infection
efficiency (data not shown). Initially, we determined whether
overexpression of Hic-5 resulted in its nuclear localization.
Subcellular fractionation showed that GFP Hic-5 was
localized in both the nucleus and the cytosol, and over-
expressing Hic-5 also caused an increase in p21cip1 levels in
the nucleus compared to control (data not shown). In
addition, overexpressing Hic-5 in NADF resulted in a
statistically significant seven-fold increase in the mRNA
(Figure 5a) and protein expression (Figure 5b) of p21cip1
compared to GFP control. Overexpressing Hic-5 in NADF
lead to a statistically significant decrease in the expression of
cyclin A as well as cyclin D1 to levels observed in HTSF
(Figure 5b). These results confirm that Hic-5 controls the
expression of key cell-cycle proteins in NADF.
Hic-5 is downstream of the TGF-b1-mediated control over cell-
cycle progression in NADF and HTSF
Since knocking down Hic-5 increased cyclin A and cyclin D1
levels in HTSF and overexpressing Hic-5 in NADF decreased
cyclin A and cyclin D1 levels, we next tested the growth
potential of these cells under these conditions. As described
above, the addition of TGF-b1 to NADF resulted in increased
Hic-5 expression (Figure 3a) and decreased cell growth
(Figure 1c). We next determined whether inhibiting Hic-5 in
turn disrupted the TGF-b1-mediated inhibition of NADF
proliferation. NADFs were transfected with either of two
separate siRNA Hic-5 duplexes (duplex #2 yielded the same
results as duplex #1, data not shown) or with control siRNA.
Cells were then cultured and the extent of Hic-5 knockdown
confirmed (490% reduction, data not shown) and growth
rates measured. Cells were seeded in serum-containing
media with or without the addition of TGF-b1, and cell
number was determined on the third day as the increase in
cell number from day 0 (cell number on day 3the cell
number on day 0). Time points taken at days 5 and 7 yielded
the same relative increase as day 3 (data not shown). We
observed that NADF knockdown for Hic-5 and TGF-b
treatment did not exhibit decreased growth (Figure 6a)
compared to siRNA control in the presence of TGF-b1. To
test whether Hic-5 was sufficient to regulate the proliferation
of NADF, we transduced these cells in the absence of siRNAs
and TGF-b and observed that overexpressing Hic-5 with the
adenoviral construct in NADF caused a significant decrease
in proliferation compared to GFP control (Figure 6b). Cell
numbers were determined at 0, 3, 5, and 7 days. The increase
in NADF cell number occurring between days 0 and 3 is
shown in Figure 6b. The increase in cell number at days 5
and 7 yielded similar results (data not shown).
Next we examined the proliferation of HTSF in the
absence of Hic-5. HTSFs were transfected either with two
separate siRNA Hic-5 duplexes (duplex #2 yielded the same
results as duplex #1, data not shown) or with control siRNA.
The extent of Hic-5 knockdown was confirmed (490%
reduction, data not shown). After transfection, HTSFs were
seeded in serum-containing media, with or without the
addition of TGF-b1, and cell numbers were determined at 0,
3, 5, and 7 days. The increase in HTSF cell number occurring
between days 0 day 3 is shown in Figure 6c. Increases in cell
number at days 5 and 7 yielded similar results (data not
shown). Knocking down Hic-5 increased the proliferation of
HTSF, but, importantly, the addition of exogenous TGF-b1 to
these cells was not sufficient to override the ablation of Hic-5
and did not decrease the proliferation of HTSF, showing that
Hic-5 was necessary to mediate the TGF-b-dependent
proliferative effects in HTSF. Importantly, while knocking
down Hic-5 in HTSF resulted in a marked increase in
proliferation, we also observed that rescuing the expression
of Hic-5 by adenoviral infection was able to inhibit
proliferation to levels observed in untreated HTSF (Figure
6c). Taken together our data show that Hic-5 is both
necessary and sufficient for TGF-b1-mediated modulation of
fibroblast proliferation in pathogenic and normal fibroblasts.
DISCUSSION
When skin is injured, quiescent fibroblasts migrate into the
wound bed, where they proliferate and differentiate into
a-smooth muscle cell actin-positive fibroblasts, termed
‘‘myofibroblasts’’ (Singer and Clark, 1999). Myofibroblasts
are contractile and synthetic cells that deposit abundant
interstitial collagens, fibronectin, and matrix-degrading
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proteases, thereby producing, contracting, and remodeling
the scar (Tomasek et al., 2002). While it is now clear that
TGF-b1 is required for the terminal differentiation of
myofibroblasts, its role in regulating fibroblast, and particu-
larly myofibroblast, proliferation is unclear. During normal,
acute wound healing, scar formation results from a finely
regulated balance of proliferation and apoptosis (Singer and
Clark, 1999). Once the wound has healed and the scar
formed (Bday 14 in rodent models), the myofibroblasts
decrease in numbers through apoptosis (Desmouliere et al.,
1995). By contrast, in pathogenic scarring, such as HTS, the
myofibroblasts are present in the wound in relatively high
numbers for months to years after injury (Ehrlich et al., 1994).
Their high numbers, in situ, along with their robust deposition
of extracellular matrix proteins and hypercontractility are
thought to be a central feature of pathogenic scarring (Tredget
et al., 1997; Scott et al., 2000). Accordingly, HTSs have been
interchangeably referred to as fibroproliferative and fibro-
contractive disorders (Grinnell, 1994; Tredget et al., 1997;
Scott et al., 2000). However, there have been surprisingly few
studies that examine the regulation of cell-cycle proteins in
pathogenic fibroblasts, including HTSF. We show here that
HTSF are in fact not hyperproliferating in comparison to
NADF and proliferation seems to be negatively regulated by
TGF-b1 in both NADF and HTSF, the latter through an
autocrine loop. We find that in HTSF, Hic-5 is constitutively
upregulated due to a stable autocrine loop that produces and
activates TGF-b1. When we inhibit the autocrine loop of
TGF-b1 in HTSF, we observe decreased expression of Hic-5
(Figure 3a), decreased expression of p21cip1 (Figure 2a), and
upregulation in proliferation to levels similar to NADF (Figure
1c). We can mimic the effect of the autocrine loop of TGF-b1
seen in HTSF by exogenously adding TGF-b1 to NADF, and
this results in the upregulation of Hic-5 (Figure 3a), increased
p21cip1 levels (Figure 2a), and subsequent decreased pro-
liferative capacity (Figure 1c). Importantly, when the expres-
sion of Hic-5 in HTSF is silenced by specific siRNAs, normal
growth is restored in these cells (Figure 6c), transducing
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Figure 5. Overexpressing Hic-5 regulates the expression of cell-cycle proteins in NADF. (a) Total RNA was isolated from HTSF and from NADF infected
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siRNA-treated HTSF with an adenoviral vector encoding
mouse Hic-5 reverses this effect (Figure 6c). When Hic-5 is
overexpressed in NADF by adenoviral transduction, growth is
markedly slowed in the absence of TGF-b1 (Figure 6b). These
data show that TGF-b1 slows the proliferation of normal and
pathogenic fibroblasts by a cellular mechanism in which Hic-
5 is both necessary and sufficient.
The role of TGF-b1 in regulating fibroblast proliferation
has been unclear for some time, in part because of differing
reports in the literature. These differences may be due to
effects of varying TGF-b1 doses, to the source of fibroblasts
assayed, or to the presence of other growth factors and
cytokines in the cultures (Thornton et al., 1990). While others
have reported that the autocrine production of TGF-b1 in
adult HTSF leads to increased entry into S-phase (Tredget
et al., 2000), we found with pediatric HTSF that the autocrine
loop mediated decreases in proliferation and entry into
S-phase. In accord with these findings, we observed
coordinated upregulation of p21cip1 and downregulation of
cyclins A and D1.
In a recent study, neonatal foreskin fibroblasts were
infected with a recombinant retrovirus encoding a mutant
form of TGF-b1 (cysteines 223 and 225 were converted to
serines) that is secreted as a constitutively active molecule
(Campaner et al., 2006). In this experimental system, TGF-b1
does not require activation and thereby mimics the autocrine
loop seen in HTSF. These fibroblasts proliferate more slowly
compared to control fibroblasts, in agreement with our
findings (Figure 1c and d). The data of Tredget et al. and
Campaner et al. leave open the possibility that pediatric/
neonatal HTSF versus adult HTSF respond differently to
autocrine stimulation of TGF-b1. By showing that Hic-5 is
necessary and sufficient to regulate TGF-b1 effects on both
NADF and HTSF proliferation, we believe that we have
discovered a central element in this regulatory mechanism.
Analysis of the signaling networks that govern Hic-5
expression and traffic to and from the nucleus may account
for differences in the effects of TGF-b1 on proliferation of
mesenchymal cells taken from a variety of tissues and
cultured under a variety of conditions.
Hic-5 is a TGF-b1- and H2O2-inducible gene product with
homology to paxillin (Shibanuma et al., 1994; Thomas et al.,
1999). It is expressed in platelets and mesenchymal cells,
such as fibroblasts and smooth muscle cells (Hagmann et al.,
1998; Yuminamochi et al., 2003). It is not present in
epithelial cells, but is upregulated in cells undergoing an
epithelial-to-mesenchymal cell transition (Tumbarello et al.,
2005; Tumbarello and Turner, 2007). To date, the regulation
or the function of Hic-5 in HTSF or other fibrotic disorders
has not yet been studied. Hic-5 localizes to both the focal
adhesions (Thomas et al., 1999) and in the nucleus
(Shibanuma et al., 2003). Recent data also showed that
suppression of Hic-5 by specific siRNAs in epithelial cells
undergoing epithelial–mesenchymal transition exhibited de-
creased RhoA activation in concert with the failure of TGF-b
to stimulate actin stress fibers and focal adhesion formation
(Tumbarello and Turner, 2007). Previously, we showed that
HTSF constitutively express supermature focal adhesions, and
the generation of supermature focal adhesion occurs through
TGF-b1 regulation. Cells that contained these larger adhe-
sions bound tighter to plasma fibronectin and had higher
contractile activity, as measured by collagen contraction
(Dabiri et al., 2006). Determining whether Hic-5 regulates
the generation of supermature focal adhesions will be crucial
to understand important aspects of pathogenic myofibro-
blasts.
Our data reported here show that Hic-5 is markedly
upregulated and readily localizes to the nucleus of HTSF due
to the autocrine loop of TGF-b1 (Figure 3a and b), and that
p21 mRNA levels are higher in HTSF and in NADF
overexpressing Hic-5, compared to control NADF (Figure
5a). Others have reported that Hic-5 transactivated the p21
promoter through two of the five Sp1 sites in the region
proximal to the TATA box. The Hic-5 effect was mediated by
a transactivation domain of Sp1 and functional interaction
with p300 through its LIM4 domain. Hic-5 was also shown to
interact functionally and physically with Smad3 through its
LIM domains and to potentiate p21 promoter activity together
with Smad3 and Sp1. Thus, Hic-5 may function as a cofactor
in the transcriptional complexes that contain Sp1, playing a
role in gene transcription in the nucleus (Shibanuma et al.,
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Figure 6. Either exogenous or autocrine TGF-b1 does not decrease
proliferation in the absence of Hic-5. TGF-b1 (10 ng/ml) was added
exogenously where indicated. (a) NADFs were transfected for 5 days with two
separate siRNA Hic-5 duplexes (duplex #2, data not shown) or scrambled
control. (b) NADFs were infected with adenovirus to GFP Hic-5 and GFP
control to overexpress Hic-5. (c) HTSFs were transfected for 5 days with two
separate siRNA Hic-5 duplexes (duplex #2, data not shown) or scrambled
control. siRNA Hic-5-transfected HTSFs were infected for 24 hours with either
an adenoviral GFP full-length Hic-5 or control construct to rescue Hic-5
levels. Cell numbers were determined after 3-day incubation using
CyQUANT assay (increase in cell number at day 3 is calculated as cell
number at day 3cell number at day 0). *Pp0.005, n¼3.
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2004). Therefore, it is important to determine whether Hic-5
could activate the transcription of other genes that are
involved in mediating the fibrotic phenotype, and these
studies are currently underway in our laboratory.
The data reported here focus on an important role for
Hic-5 in pathogenic fibroblasts in slowing cell proliferation in
response to TGF-b1. HTSF have been previously shown to be
resistant to apoptosis through the upregulation of bcl-2
(Moulin et al., 2004); others have showed that TGF-b1 has
antiapoptotic effects (Zhang and Phan, 1999). Consistent with
this model, we find that the HTSF used in our study also
upregulate bcl-2 (data not shown) and do not readily undergo
apoptosis compared to NADF (Figure S1).
In conclusion, TGF-b1 mediates a slowing of normal
dermal fibroblast proliferation and may represent a critical
early step in myofibroblast differentiation. The dampened
proliferation that we observe in HTSF is mediated by an
autocrine loop in which active TGF-b1 is produced. In NADF
and HTSF, the TGF-b1-dependent effects on proliferation are
mediated by a mechanism in which Hic-5 is both necessary
and sufficient. We believe that these findings provide a new
avenue for research on the pathogenic myofibroblast
phenotype as it occurs in HTSF and potentially other fibrotic
skin diseases.
MATERIALS AND METHODS
Cell culture
All cells used in these studies were cultured (371C and 5% CO2) in
serum-containing media, which consisted of Dulbecco’s modifica-
tion of Eagle’s Minimum Essential Medium, 10% fetal bovine serum,
and 1% penicillin–streptomycin (all of which were obtained from
Gibco Invitrogen Corporation, Carlsbad, CA). NADFs were pur-
chased from Clonetics-Cambrex BioScience (Walkersville, MD).
HTSFs were isolated from biopsies taken from HTSs resected
therapeutically from pediatric patients at Shriner’s Burn Hospital
and Massachusetts General Hospital (Boston, MA). Tissue was
processed as described in Dabiri et al. (2006). All tissues were
acquired anonymously under protocols approved by the relevant
Medical and Ethical Committees of the Shriners Hospital for
Children–Boston in accordance with the Declaration of Helsinki
Principles and patients gave their written, informed consent.
Growth curve
Cell growth was measured using CyQUANTs Cell Proliferation
Assay Kit (C-7026; Invitrogen, Carlsbad, CA). In brief, NADF (1 103
cells) or HTSF (1 103 cells) were plated in duplicate or triplicate in
96-well dishes (Corning Inc., Corning, NY) in complete media with
or without the addition of 10 ng/ml of TGF-b1 (R&D Systems,
Minneapolis, MN) or 20 mg/ml anti-TGF-b (R&D Systems). Plates
were incubated for 0, 3, 5, and 7 days, inverted to remove the
medium from the wells, and treated according to the manufacturer’s
protocol. Plates were read on Spectra Max Gemini-EM (Molecular
Devices, Sunnyvale, CA) with an excitation and emission spectrum
480 and 520 nm, respectively.
BrdU incorporation
HTSF (5 103 cells) or NADF (5 103 cells) were plated in serum-
free media (DMEM 1:1, Hams F12 1:1, transferrin 5mg/ml, insulin
5 107 M, ascorbate 0.2mM, glutamine 1:100, and penicillin–strep-
tomycin 1:100) for 18 hours in LabtekTM chambers (Nalge Nunc
International, Naperville, IL) at 371C. Cells were washed three times
with Dulbecco’s phosphate-buffered saline (Gibco Invitrogen Inter-
national) and to each well, DMEM-containing serum was added,
10 mg/ml of BrdU (Biodesign International, Saco, ME), with or
without the addition of 10 ng/ml of TGF-b1. In some wells, anti-TGF-
b (20 mg/ml) was also added as indicated. Cells were incubated
(24 hours), washed with Dulbecco’s phosphate-buffered saline (PBS),
fixed with 3.7% formaldehyde (Sigma, St Louis, MO) in Dulbecco’s
phosphate-buffered saline (10minutes), permeabilized with 0.5%
Triton X-100 (5minutes) (Sigma), blocked (1 hour) with 2% BSA
(Sigma) in PBS and then DNase (Promega, Madison, WI) treated for
30minutes. All primary and secondary antibodies were diluted in
2% BSA (Sigma) in PBS. Samples were then incubated sequentially
with mAb against BrdU (10 mg/ml in 2% BSA/PBS) and then with a
mixture of donkey anti-sheep Alexa Fluor 488 (1:200, in 2% BSA/
PBS) and Hoechst 33342 (1:1,000) (both from Molecular Probes,
Sunnyvale, CA). Coverslips were mounted in Gelmount (Biomedia
Corp., Foster City, CA) and slides were analyzed on an Olympus
BX60 microscope using  10 objective. Images were captured with
attached Cooke Sensicam digital camera and deconvolved using
Slidebook 3.0.10.3 software (FFTW licensed from Massachusetts
Institute of Technology, Cambridge, MA). The percent positive BrdU
incorporation was determined by dividing the number of nuclei
labeled with both BrdU (green) and Hoescht (blue) by the total
number of nuclei (blue) 100.
Luciferase MLEC assay
MLECs (MLECs-clone 32) were stably transfected with an 800 bp
fragment (799- þ 71) of the 50-end of the human PAI-1 gene
promoter engineered to drive the firefly luciferase reporter gene in a
p19LUC-based vector containing the neomycin-resistance gene from
pMAMneo (Abe et al., 1994). Transfected MLECs were maintained in
DMEM supplemented with 10% fetal bovine serum, penicillin
(100U/ml), streptomycin (100 mg/ml), L-glutamine, and G418 (Ge-
neticin, 200 mg/ml). In some experiments, MLECs (5 104 cells) were
plated either with or without the addition of anti-TGF-b (10 ng/ml)
and/or active TGF-b1 (5 ng/ml) to test the efficiency of blocking
conditions. In other experiments, MLECs were co-cultured (371C,
5% CO2, and 24 hours) with NADF (5 104 cells) or HTSF (5 104
cells) in serum-containing media (as described above) with or
without the addition of anti-TGF-b (20 mg/ml). Luciferase activity was
measured by addition of Bright-GloTM Luciferase Assay System
(Promega) to cells (5minutes) and quantitated on MonolightTM
3010 reader (Pharmingen, Franklin Lakes, NJ).
Western blot analysis
NADF and HTSF lysates were analyzed for protein expression by
Western blotting with the following primary antibodies at a
concentration of 1:1,000: cyclin D1 (DCS-6; BD Biosciences, San
Jose, CA), cyclin A (H 432; Santa Cruz Biotechnology, Santa Cruz,
CA), p21cip1 (sx-118; BD Biosciences), p15ink4b (Cell Signaling,
Danvers, MA), Hic-5 (BD Transduction, Franklin Lakes, NJ), RhoGDI
(Santa Cruz Biotechnology), H2A (Cell Signaling), and Erk 1/2 (Santa
Cruz Biotechnology). Western blots were developed using Super-
Signal chemiluminescent substrate (Pierce, Rockford, IL) and
quantitated with a Fluor-S MultiImager and Quantity-One software
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(Bio-Rad, Hercules, CA). Membranes were stripped using Restore
Stripping (Pierce) and reprobed (no more than once) with other
antibodies.
Subcellular fractionation
Either NADFs (5 105 cells) or HTSFs (5 105 cells) were cultured
in DMEM plus serum for 24 hours with either TGF-b1 (10 ng/ml) or
anti-TGF-b1 (20 mg/ml) where indicated. Cells were washed with
ice-cold PBS twice on ice and lysed in Bicarbonate-Nonidet (BN)
buffer (1ml) (15mM Tris, pH 7.5, 60mM KCl, 5mM MgCl2, 156 nM
NaCl, and 250 nM sucrose) containing 0.15% NP40 (Sigma) on ice.
Cells were then pelleted (500 g for 4minutes at 41C) and the
cytosolic fraction (supernatant) was removed. The nuclear fraction
(pellet) was resuspended in BN buffer (1ml) without NP40, spun at
500 g for 4minutes at 41C, and the supernatant was discarded. To
the pellet (nuclear fraction), 100ml of 1 sample buffer with
dithiothreitol was added and 1/10 of the sample (10 ml) was analyzed
by Western blot analysis. Of the 1,000 ml of the cytosolic fraction
(supernatant), 25ml of cytosol fraction was added to 75ml of 4
sample buffer with dithiothreitol. Protein expression was analyzed
by Western blot analysis, as described above.
RNA interference
NADFs or HTSFs were transfected with siRNA (Dharmacon,
Lafayette, CO) using OligofectAMINE (Invitrogen). Hic-5 knock-
down was performed using individual siRNA sequences: duplex #1
(GGAGCUGGAUAGACUGAUGUU) and duplex #2 (GGACCAGU
CUGAAGAUAAGUU). Cells were transfected for 4 hours in
OptiMem (Gibco Invitrogen Corporation) and re-fed with DMEM
with serum. Cells were trypsinized after 5 days and replated for
experiments.
Adenovirus production
Full-length mouse Hic-5 cDNA (kindly provided by Dr Sheila
Thomas, Harvard Medical School, Boston, MA) was subcloned into
pEGFPc1 (BD Clontech, Mountain View, CA). Adenovirus was
produced utilizing the Adeno-X system according to the manufac-
turer’s instructions (BD Clontech). Briefly, the GFP Hic-5 was
excised from the pEGFPc1 vector and subcloned into the pShuttle
vector. Restriction digest of the pShuttle construct with the unique
endonucleases I-Ceu I and PI-Sce I was performed followed by
subcloning into the adenovirus vector. Adenoviral stocks were
amplified in Ad-HEK cells (Stratagene, La Jolla, CA) and titered by
limited dilution assay in 96-well plates. The GFP adenovirus was
kindly provided by Dr A Hassid (University of Tennessee, Memphis,
TN). Fifty thousand cells were plated in serum-containing media for
24 hours. Next day cells were washed twice with serum-free media,
then serum-free media was added and cells were infected with an
multiplicity of infection of 100 p.f.u./cell. Experiments were per-
formed 24 hours following infection.
Reverse transcriptase-PCR
Twenty-four hours postoverexpression, total RNA was extracted from
cells using the PURESCRIPT RNA Isolation kit (Gentra Systems,
Minneapolis, MN, USA). RNA (1/10th) was reverse transcribed and
1mg of the resulting cDNA was utilized to detect mRNA abundance
with primers for p21cip1 (forward: 50-GCGATGGAACTTCGACTTT
GT; reverse: 50-GGGCTTCCTCTTGGAGAAGAT) and glyceralde-
hyde-3-phosphate dehydrogenase as control (forward: 50-CATGGCC
TCCAAGGAGTAAG; reverse: 50-GGTTGSGCACAGGGTACTTTA).
All primers were designed to give B200–350bp products. PCR
reactions were carried out in PCR SuperMix (Invitrogen, Carlsbad,
CA) and 2.5 mM of each primer. PCR conditions were 951C for
5minutes followed by 941C for 90 seconds, 641C for 90 seconds, and
721C for 120 seconds for a total of 45 cycles. PCR products were run
on a 2% agarose gel, stained with ethidium bromide, and visualized
using a Bio-Rad Gel-Doc 2000. Signals were quantified using
Quantity One software (Bio-Rad).
TUNEL assay
NADFs and HTSFs were analyzed for apoptosis according to the
manufacturer’s protocol using the DeadEnd Fluorometric TUNEL
System assay kit (Promega). Experimental conditions were based on
those used in the BrdU assay with minor modifications. Briefly,
5 103 NADFs or HTSFs were plated in serum-containing media
with or without the addition of 10ng/ml of TGF-b1 or 20mg/ml of
anti-TGF-b in Labtek chambers (Nalge Nunc International) at 371C for
3 days. As a positive control, anisomycin (10mg/ml) was added to
nontreated cells during the last 24 hours to induce apoptosis; DMSO
was used a vehicle control. Some cells were treated with DNase I to
fragment chromosomal DNA and served as positive assay control (data
not shown). After fluorescein-12-dUTP nick end labeling was
completed and the cells were counterstained with 1mg/ml propidium
iodide. Coverslips were mounted in Gelmount (Biomedia Corp.) and
slides were analyzed on an Olympus BX60 microscope using a  20
objective. Images were captured with attached Cooke Sensicam digital
camera and deconvolved using Slidebook 3.0.10.3 software (FFTW
licensed fromMassachusetts Institute of Technology, Cambridge, MA).
Statistics
Statistical comparisons between sample groups were made using an
analysis of variance with Pp0.005 indicating a significant difference
between the groups.
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Figure S1. The effect of TGF-b1 on apoptosis of NADF and HTSF.
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